Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics

There has been conflicting evidence on the impact of bilateral breast cancer (BBC) on the survival and management of patients. The objectives of this study were to address the incidence of BBC and to investigate its characteristics and outcome compared to unilateral cancer. Data were acquired from the prospectively maintained NUIG breast cancer database between 1988 and 2008. BBC were then categorized as synchronous (within 12 months) or metachronous (after 12 months of first tumour). SPSS was used for data analysis. The incidence of BBC in our population was 4.4% (112 of 2,524). Of those 2.1% were synchronous while 2.3% were metachronous. Compared to unilateral cases, bilateral cancer patients were younger (P = 0.021) and had smaller size (P = 0.001) and earlier stage (P < 0.001) tumours at diagnosis. We identified the HER2/neu positivity as a risk factor for developing contralateral breast tumour and ER negativity as a risk factor for developing metachronous tumours. While there was no significant difference in survival for patients with bilateral compared to unilateral tumour (P > 0.05), the synchronous tumour was associated with poorer survival (P = 0.010) in comparison to metachronous tumour. This large single-institutional experience does not support the increasing practice of prophylactic mastectomy but does justify regular follow-up with mammography for early detection of contralateral tumour.

[1]  L. Pierce,et al.  Cancer in the contralateral breast after radiotherapy for breast cancer. , 1992, The New England journal of medicine.

[2]  Masato Takahashi,et al.  The impact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer , 2005, Breast cancer.

[3]  S. Schnitt,et al.  Breast‐conserving therapy for Stage I‐II synchronous bilateral breast carcinoma , 1997, Cancer.

[4]  T. Sellers,et al.  Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Hakama,et al.  Survival from contralateral breast cancer , 1999, Breast Cancer Research and Treatment.

[6]  Mitchell D Schnall,et al.  MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. , 2003, Radiology.

[7]  S. Singletary,et al.  A case–control study of unilateral and bilateral breast carcinoma patients , 2001, Cancer.

[8]  Michael Laniado,et al.  MR imaging of the contralateral breast in patients after breast-conserving therapy , 2004, European Radiology.

[9]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[10]  C. Stegmaier,et al.  Clinical epidemiology of bilateral breast cancer , 1993, Cancer.

[11]  B. Asselain,et al.  Simultaneous bilateral breast carcinomas: a retrospective review of 149 cases. , 1994, International journal of radiation oncology, biology, physics.

[12]  Cancer in the contralateral breast after radiotherapy for breast cancer. , 1992, The New England journal of medicine.

[13]  D J Schaid,et al.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. , 1999, The New England journal of medicine.

[14]  B. Emami,et al.  Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. , 2003, International journal of radiation oncology, biology, physics.

[15]  C. Gatsonis,et al.  MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. , 2007, The New England journal of medicine.

[16]  I. Bedrosian,et al.  Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. , 2010, Journal of the National Cancer Institute.

[17]  G. Makari-Judson,et al.  Contralateral Breast Cancer: Factors Associated with Stage and Size at Presentation , 2004, The breast journal.

[18]  H. D. de Koning,et al.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.

[19]  P. Kotin,et al.  Possible role of trauma as a cocarcinogen. Case report on an oil worker , 1953, Cancer.

[20]  J. Cuzick,et al.  Bilateral primary breast cancer: A prospective study of disease incidence , 1984, The British journal of surgery.

[21]  S. Kaplan.  [Bilateral breast cancer]. , 1955, Prensa medica argentina.

[22]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[23]  F. Ong,et al.  Synchronous, bilateral breast cancer: prognostic value and incidence. , 2003, Breast.

[24]  L. Mariani,et al.  Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? , 1998, European journal of cancer.

[25]  R. Thisted,et al.  The impact of contralateral breast cancer on the outcome of breast cancer patients treated by mastectomy. , 2000, Cancer journal.

[26]  D. Heron,et al.  Bilateral breast carcinoma , 2000, Cancer.

[27]  T. Tuttle,et al.  Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Sellers,et al.  Reoperations after prophylactic mastectomy with or without implant reconstruction , 2003, Cancer.

[29]  I. Olivotto,et al.  Diagnosis of Metachronous Contralateral Breast Cancer , 2001, The breast journal.

[30]  M. Hakama,et al.  Risk factors for contralateral breast cancer in Chennai (Madras), India. , 1998, International journal of epidemiology.

[31]  R. Weichselbaum,et al.  Efficacy of Breast Conservation Therapy in Early Stage Bilateral Breast Cancer , 1999, The breast journal.

[32]  L. Newman.  Contralateral Breast Cancer: Factors Associated With Stage and Size at Presentation , 2005 .

[33]  M. Kerin,et al.  Prospective matched‐pair comparison of outcome after treatment for lobular and ductal breast carcinoma , 2008, The British journal of surgery.

[34]  A. Schauer,et al.  Eight-year results of a prospective non-randomised study on therapy of small breast cancer. The German Breast Cancer Study Group (GBSG). , 1998, European journal of cancer.

[35]  N. Risch,et al.  Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. , 1992, American journal of epidemiology.

[36]  W. Thompson,et al.  Epidemiology of contralateral breast cancer. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[37]  K. Czene,et al.  Genetic implications of bilateral breast cancer: a population based cohort study. , 2005, The Lancet. Oncology.

[38]  C. Flowers,et al.  Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population , 2009, BMC health services research.

[39]  R. Pommier,et al.  Incidence and outcomes of contralateral breast cancers. , 2008, American journal of surgery.

[40]  J. Andersen,et al.  Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. , 2000, American journal of surgery.

[41]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[42]  M. Lesser,et al.  Multicentricity and bilaterality in invasive breast carcinoma. , 1982, Surgery.

[43]  A. Jacobsen,et al.  Adjuvant radiotherapy and risk of contralateral breast cancer. , 1992, Journal of the National Cancer Institute.

[44]  G. Vlastos,et al.  Survival after bilateral breast cancer: results from a population-based study , 2007, Breast Cancer Research and Treatment.

[45]  H. Adami,et al.  Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population‐based case‐control study , 1985, Cancer.

[46]  B. E. F. Isher,et al.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .

[47]  R. Prescott,et al.  The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[48]  H. Gogas,et al.  Bilateral breast cancer. , 1993, The American surgeon.

[49]  C. Begg,et al.  Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. , 2008, Journal of the National Cancer Institute.

[50]  M. Hiraoka,et al.  Bilateral breast-conserving therapy for bilateral breast cancer: Results and consideration of radiation technique , 2005, Breast cancer.

[51]  I. Fentiman,et al.  Prognosis of synchronous bilateral breast cancer , 2009, The British journal of surgery.

[52]  C. Boetes,et al.  Screening women at increased risk with MRI , 2005, Cancer imaging : the official publication of the International Cancer Imaging Society.

[53]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[54]  N. Hylton,et al.  Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: Results from the International Breast Magnetic Resonance Consortium (IBMC) trial , 2005, Journal of surgical oncology.